Expect upside in Sun Pharma: Abhishek Sharma

Abhishek Sharma, pharma analyst at IIFL is of the view that one may see upside in Sun Pharmaceutical Industries.

Abhishek Sharma, pharma analyst at IIFL told CNBC-TV18, " Ranbaxy Laboratories has been a great company all this while, it was one of the pioneers for the Indian pharma industry in the way they went to the US generics. It is still, at this date, there are obviously issues which the company has faced in terms of the USFDA issues, in terms of their forex management. But apart from that, we believe that Ranbaxy comes with a lot of strengths to the table and if managed and integrated very well it provides a significant upside to Sun Pharmaceutical Industries  from here."

"There is a cross-sell opportunity for Sun Pharma to do with the Ranbaxy's infrastructure in rest of world markets. And we are now seeing that a combine entity would have a USD 300 million annual R&D. So, with that kind of a number, we are actually reaching Teva's R&D, generic R&D budgets every year and we hope to see the impact of that huge R&D number
into the pipelines over the next 2-3 years," he said.

Anda sedang membaca artikel tentang

Expect upside in Sun Pharma: Abhishek Sharma

Dengan url

http://sehatgayahidup.blogspot.com/2015/03/expect-upside-in-sun-pharma-abhishek.html?m=0

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Expect upside in Sun Pharma: Abhishek Sharma

namun jangan lupa untuk meletakkan link

Expect upside in Sun Pharma: Abhishek Sharma

sebagai sumbernya